October 7, 2016 / 3:11 PM / 10 months ago

BRIEF-Kite pharma presents 12-month follow-up data from ZUMA-1 Phase 1

1 Min Read

Oct 7 (Reuters) - Kite Pharma Inc :

* Kite Pharma Inc says encouraged that complete remission rate of 43 percent in phase 1 portion of study continues through month 12

* Co plans to report additional data on durability of response to KTE-C19 from phase 2 portion of ZUMA-1 in 2017

* Month follow-up data from ZUMA-1 phase 1 at the european society for medical oncology (ESMO) annual congress

* Kte-C19 related adverse events consisted predominantly of cytokine release syndrome (CRS) and neurotoxicity which were generally reversible Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below